Descrizione del progetto
Una nuova radioteranostica funzionale basata su complessi supramolecolari
La radioteranostica è un’area emergente della medicina nucleare che consente di attuare simultaneamente immaginografia e terapia erogando radiazioni mirate ai nuclei cellulari per indurre la morte delle cellule. In genere, questa tecnica si basa su radiofarmaci iniettabili sotto forma di singole molecole che incorporano un radioisotopo terapeutico o diagnostico. Il progetto SMARTdrugs, finanziato dal CEI, intende sfruttare lo straordinario potenziale della chimica supramolecolare per sviluppare una nuova classe di radioteranostica multifunzionale. Il team intende creare questi farmaci radioteranostici supramolecolari attraverso l’autoassemblaggio di complessi di coordinazione supramolecolari ospite-ospite, utilizzando come impalcature molecole a incastro. Sebbene i ricercatori si concentreranno inizialmente sui tumori, i loro risultati saranno rilevanti anche per altre applicazioni di somministrazione di farmaci e utili per la ricerca di base sulle interazioni biologiche.
Obiettivo
From diagnostic applications in the quantification and characterisation of biomarker expression in cancer patients, through to molecularly targeted radionuclide therapy, radiopharmaceuticals are at the frontline of modern personalised medicine. The radical long-term vision of SMARTdrugs is to harness the untapped potential of supramolecular chemistry to create a new class of therapies - radiotheranostics - which combine both diagnostic and therapeutic radionuclides in one compound. By using the self-assembly of host-guest supramolecular coordination complexes and molecularly interlocked molecules as scaffolds for creating supramolecular radiotheranostic drugs, new methods for radiotheranostic synthesis that break away from conventional medicinal chemistry concept will be introduced. SMARTdrugs will establish a proof-of-concept demonstrating the utility of non-covalent systems in the design of multifunctional radiotheranostic agents with tailored pharmacokinetics, and their application in challenging drug-delivery scenarios including targeted delivery to cancers of the lung and brain.
Our 3 main objectives:
Objective 1 – Develop new chemical landscapes using non-covalent bonding to create functionalised supramolecular compounds for cancer-specific theranostics
Objective 2 – Elucidate the key relationships between supramolecular radiotheranostics and the complex tumour microenvironment that determine drug efficacy in vivo
Objective 3 – Perform head-to-head studies to establish a proof-of-principle that supramolecular chemistry is a viable alternative to classical radiopharmaceutical design
The long-term goal is to establish a new chemical landscape for radiotheranostic design, and to facilitate clinical translation of this new technology. Successful experiments will lay the foundations for exploiting supramolecular chemistry in the wider context of drug delivery and theranostics, and for studying biological interactions at the cellular to whole-organism levels.
Campo scientifico
- medical and health sciencesbasic medicinemedicinal chemistry
- natural scienceschemical sciencesnuclear chemistryradiochemistry
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencesbiological sciencesbiological behavioural sciencesethologybiological interactions
Parole chiave
Programma(i)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Invito a presentare proposte
HORIZON-EIC-2023-PATHFINDEROPEN-01
Vedi altri progetti per questo bandoMeccanismo di finanziamento
HORIZON-EIC - HORIZON EIC GrantsCoordinatore
80333 Muenchen
Germania